HC Wainwright Cuts GT Biopharma (OTCMKTS:GTBP) Price Target to $5.00

GT Biopharma (OTCMKTS:GTBPGet Rating) had its price objective reduced by HC Wainwright from $25.00 to $5.00 in a research note issued to investors on Tuesday, The Fly reports. They currently have a buy rating on the stock.

Separately, Roth Capital lowered shares of GT Biopharma from a buy rating to a neutral rating in a research report on Thursday, August 11th.

GT Biopharma Price Performance

Shares of GT Biopharma stock opened at $2.20 on Tuesday. GT Biopharma has a 1 year low of $1.51 and a 1 year high of $8.28. The firm has a market cap of $68.40 million, a PE ratio of -2.29 and a beta of 0.54. The company has a 50 day simple moving average of $2.70 and a two-hundred day simple moving average of $2.68.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in GTBP. Atria Wealth Solutions Inc. purchased a new position in shares of GT Biopharma during the first quarter worth approximately $29,000. Russell Investments Group Ltd. purchased a new position in shares of GT Biopharma in the first quarter worth $31,000. Sigma Planning Corp purchased a new position in shares of GT Biopharma in the first quarter worth $62,000. Allspring Global Investments Holdings LLC purchased a new position in GT Biopharma during the 1st quarter valued at $74,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new position in GT Biopharma during the 4th quarter valued at $107,000. 10.09% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

(Get Rating)

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.

Read More

The Fly logo

Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.